PetMedix, a Cambridge UK-based animal health company, raised $37M in Series B funding.
The round was led by Tencent and Kyoritsu Holdings with participation from Digitalis Ventures, Parkwalk Advisors and Cambridge Innovation Capital.
The company intends to use the funds to advance its innovative pipeline through clinical development.
Led by Tom Weaver, CEO, and Dr Dave Lowery, Chief Product Development Officer, PetMedix provides species-specific therapeutic antibodies to veterinary medicine. The company’s internal discovery programs will continue to advance through development on their way to regulatory approval.
PetMedix was spun out the lab of Prof Allan Bradley FRS in 2018, based on the PhD work of his student, now PetMedix co-founder, Jolyon Martin. While the initial focus will be the United States, PetMedix has built an international organisation and financing syndicate to support efforts in European and Asian markets as well.